Hyperspectral imaging for quantitative assessment of hepatic steatosis in human liver allografts.
hyperspectral imaging
liver biopsy
liver transplantation
non-invasive
optical method
steatosis
tissue lipid index
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
25
04
2022
received:
02
03
2022
accepted:
01
05
2022
pubmed:
28
5
2022
medline:
11
8
2022
entrez:
27
5
2022
Statut:
ppublish
Résumé
In liver transplantation (LT), steatosis is commonly judged to be a risk factor for graft dysfunction, and quantitative assessment of hepatic steatosis remains crucial. Liver biopsy as the gold standard for evaluation of hepatic steatosis has certain drawbacks, that is, invasiveness, and intra- and inter-observer variability. A non-invasive, quantitative modality could replace liver biopsy and eliminate these disadvantages, but has not yet been evaluated in human LT. We performed a pilot study to evaluate the feasibility and accuracy of hyperspectral imaging (HSI) in the assessment of hepatic steatosis of human liver allografts for transplantation. Thirteen deceased donor liver allografts were included in the study. The degree of steatosis was assessed by means of conventional liver biopsy as well as HSI, performed at the end of back-table preparation, during normothermic machine perfusion (NMP), and after reperfusion in the recipient. Organ donors were 51 [30-83] years old, and 61.5% were male. Donor body mass index was 24.2 [16.5-38.0] kg/m HSI may safely be applied for accurate assessment of hepatic steatosis in human liver grafts. Certainly, TLI needs further assessment and validation in larger sample sizes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14736Informations de copyright
© 2022 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd.
Références
Hamar M, Selzner M. Steatotic donor livers: where is the risk-benefit maximized?. Liver Transpl. 2017;23(S1):S34-S39.
Miyachi Y, Yagi S, Hirata M, et al. Etiology of liver steatosis influences the severity of Ischemia/Reperfusion injury and survival after liver transplantation in rats. Liver Transpl. 2020;26(11):1504-1515.
Fang JM, Cheng J, Chang MF, Ahn J, Westerhoff M. Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint. Mod Pathol. 2021;34(10):1955-1962.
El-Badry AM, Breitenstein S, Jochum W, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg. 2009;250(5):691-697.
Salvi M, Molinaro L, Metovic J, et al. Fully automated quantitative assessment of hepatic steatosis in liver transplants. Comput Biol Med. 2020;123:103836.
Lu G, Fei B. Medical hyperspectral imaging: a review. J Biomed Opt. 2014;19(1):10901.
Kulcke A, Holmer A, Wahl P, Siemers F, Wild T, Daeschlein G. A compact hyperspectral camera for measurement of perfusion parameters in medicine. Biomed Tech (Berl). 2018;63(5):519-527.
Sucher R, Athanasios A, Kohler H, et al. Hyperspectral Imaging (HSI) in anatomic left liver resection. Int J Surg Case Rep. 2019;62:108-111.
Kohler H, Maktabi M, Barberio M, et al. Hyperspectral imaging for intraoperative space-resolved quantification of tissue fat content. In: Burgert O, Hirt B, eds. Conference transcripts of the 18th annual CURAC meeting. German Society for Computer- and Robot-Assisted Surgery; 2019:37-40.
Mergental H, Laing RW, Kirkham AJ, et al. Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat Commun. 2020;11(1):2939.
Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56.
Okubo K, Kitagawa Y, Hosokawa N, et al. Visualization of quantitative lipid distribution in mouse liver through near-infrared hyperspectral imaging. Biomed Opt Express. 2021;12(2):823-835.
Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949.
Chu MJ, Dare AJ, Phillips AR, Bartlett AS. Donor hepatic steatosis and outcome after liver transplantation: a systematic review. J Gastrointest Surg. 2015;19(9):1713-1724.
Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16(7):874-884.
Linares I, Hamar M, Selzner N, Selzner M. Steatosis in liver transplantation: current limitations and future strategies. Transplantation. 2019;103(1):78-90.
Nativ NI, Maguire TJ, Yarmush G, et al. Liver defatting: an alternative approach to enable steatotic liver transplantation. Am J Transplant. 2012;12(12):3176-3183.
Urasaki Y, Zhang C, Cheng JX, Le TT. Quantitative assessment of liver steatosis and affected pathways with molecular imaging and proteomic profiling. Sci Rep. 2018;8(1):3606.
Orman ES, ASt Barritt, Wheeler SB, Hayashi PH. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl. 2013;19(1):59-68.
de Boer LL, Molenkamp BG, Bydlon TM, et al. Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries. Breast Cancer Res Treat. 2015;152(3):509-518.
Mazilescu LI, Selzner M, Selzner N. Defatting strategies in the current era of liver steatosis. JHEP Rep. 2021;3(3):100265.
Boteon YL, Attard J, Boteon A, et al. Manipulation of lipid metabolism during normothermic machine perfusion: effect of defatting therapies on donor liver functional recovery. Liver Transpl. 2019;25(7):1007-1022.
Felli E, Al-Taher M, Collins T, et al. Hyperspectral evaluation of hepatic oxygenation in a model of total vs. arterial liver ischaemia. Sci Rep. 2020;10(1):15441.
Czigany Z, Lurje I, Tolba RH, Neumann UP, Tacke F, Lurje G. Machine perfusion for liver transplantation in the era of marginal organs-New kids on the block. Liver Int. 2019;39(2):228-249.